Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Yuko Takahashi; Takayuki Iwamoto; Yoko Suzuki; Yukiko Kajiwara; Minami Hatono; Takahiro Tsukioki; Kengo Kawada; Mariko Kochi; Hirokuni Ikeda; Tadahiko Shien; Naruto Taira; Junji Matsuoka; Hiroyoshi Doihara; Shinichi Toyooka

doi:10.1016/j.clbc.2019.07.001

Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Yuko Takahashi, Takayuki Iwamoto, Yoko Suzuki, Yukiko Kajiwara, Minami Hatono, Takahiro Tsukioki, Kengo Kawada, Mariko Kochi, Hirokuni Ikeda, Tadahiko Shien, Naruto Taira, Junji Matsuoka, Hiroyoshi Doihara, Shinichi Toyooka

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

Original language	English
Pages (from-to)	117-124.e4
Journal	Clinical Breast Cancer
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.clbc.2019.07.001
Publication status	Published - Apr 2020

Keywords

Gene expression
Hormone receptor positive
Residual tumor burden
Targeted therapy
Triple negative

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2019.07.001

Cite this

Takahashi, Y., Iwamoto, T., Suzuki, Y., Kajiwara, Y., Hatono, M., Tsukioki, T., Kawada, K., Kochi, M., Ikeda, H., Shien, T., Taira, N., Matsuoka, J., Doihara, H., & Toyooka, S. (2020). Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 20(2), 117-124.e4. https://doi.org/10.1016/j.clbc.2019.07.001

Takahashi, Y , Iwamoto, T, Suzuki, Y, Kajiwara, Y, Hatono, M, Tsukioki, T, Kawada, K, Kochi, M, Ikeda, H, Shien, T, Taira, N, Matsuoka, J, Doihara, H & Toyooka, S 2020, 'Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer', Clinical Breast Cancer, vol. 20, no. 2, pp. 117-124.e4. https://doi.org/10.1016/j.clbc.2019.07.001

@article{7b30469cad964eec9c5b9ce9c9313601,

title = "Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer",

abstract = "Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.",

keywords = "Gene expression, Hormone receptor positive, Residual tumor burden, Targeted therapy, Triple negative",

author = "Yuko Takahashi and Takayuki Iwamoto and Yoko Suzuki and Yukiko Kajiwara and Minami Hatono and Takahiro Tsukioki and Kengo Kawada and Mariko Kochi and Hirokuni Ikeda and Tadahiko Shien and Naruto Taira and Junji Matsuoka and Hiroyoshi Doihara and Shinichi Toyooka",

note = "Funding Information: This study was funded by subsidies for operating expenses at the Department of Breast and Endocrine Surgery, Okayama University Hospital . Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = apr,

doi = "10.1016/j.clbc.2019.07.001",

language = "English",

volume = "20",

pages = "117--124.e4",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

AU - Takahashi, Yuko

AU - Iwamoto, Takayuki

AU - Suzuki, Yoko

AU - Kajiwara, Yukiko

AU - Hatono, Minami

AU - Tsukioki, Takahiro

AU - Kawada, Kengo

AU - Kochi, Mariko

AU - Ikeda, Hirokuni

AU - Shien, Tadahiko

AU - Taira, Naruto

AU - Matsuoka, Junji

AU - Doihara, Hiroyoshi

AU - Toyooka, Shinichi

N1 - Funding Information: This study was funded by subsidies for operating expenses at the Department of Breast and Endocrine Surgery, Okayama University Hospital . Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/4

Y1 - 2020/4

N2 - Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

AB - Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

KW - Gene expression

KW - Hormone receptor positive

KW - Residual tumor burden

KW - Targeted therapy

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=85072644046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072644046&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2019.07.001

DO - 10.1016/j.clbc.2019.07.001

M3 - Article

C2 - 31570267

AN - SCOPUS:85072644046

SN - 1526-8209

VL - 20

SP - 117-124.e4

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 2

ER -

Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this